CASOLA STEFANO

Name: Stefano Casola
Affiliation: IFOM-The AIRC Institute of Molecular Oncology, Milan, Italy
Email: stefano.casola@ifom.eu
ORCID https://orcid.org/0000-0001-5580-0986

Education:
• 1999: Ph.D., University of Naples Federico II, Italy
• 1993: M.D., University of Naples Federico II, Italy

Licensure:
• 1994: Italian Medical License (registration)

Post-doctoral training:
• 1997-2001: Institute of Genetics, University of Cologne, Germany, Laboratory of Klaus Rajewsky

Academic and Research Appointments:
• 2024-present: Professor of Pathology, Department of Medical Biotechnology and Translational Medicine, University of Milan, Milano, Italy
• 2013-present: Senior group leader, IFOM-The AIRC Institute of Molecular Oncology, Milan, Italy
• 2006-2013: Junior group leader, IFOM-The AIRC Institute of Molecular Oncology, Milan, Italy
• 2001-2006: Instructor, Department of Pathology, Harvard Medical School, Boston, USA
• 2001-2006: Junior Investigator, CBR Institute for Biomedical Research, Boston, USA

Academic Service and Teaching
• 2023-present: Member of the Academic Board, Graduate Program in “Translational Medicine,” Scuola Universitaria Superiore Sant'Anna, Pisa, Italy
• 2006-present: Member of the Academic Board and Lecturer, European School of Molecular Medicine (SEMM), Graduate Program in “Systems Medicine,” University of Milan, Milan, Italy

Honors and awards:
• 2006: Career Development Award, Giovanni Armenise Harvard Foundation.
• 2006: New AIRC Start-Up Unit Award, Italian Association for Cancer Research (declined due to overlap with the Giovanni Armenise–Harvard Foundation Career Development Award).
• 1999: Postdoctoral Fellowship, Cancer Research Institute.
• 1997: Postdoctoral Fellowship, Alexander von Humboldt Foundation.
• 1997: Postdoctoral Fellowship, European Molecular Biology Organization.
• 1997: Postdoctoral Fellowship, Human Frontier Science Program.
• 1996: Award for top scientific publication as a graduate student, Italian Society of Biophysics and Molecular Biology.
Professional Memberships:
• 2025–present: Member, American Association for Cancer Research
• 2019–present: Member, Fondazione Italiana Linfomi
• 2018–present: Member, American Society of Hematology
• 2014–present: Member, European Hematology Association
• 2009–present: Member, Italian Society of Immunology Clinical Immunology and Allergology
Research achievements
As of April 28, 2026, Dr. Casola’s research activity is documented by 69 articles and reviews published in peer-reviewed international journals. His research focuses on the genetic and epigenetic mechanisms that regulate B-cell development and immune function in both physiological and pathological conditions. In parallel, Dr. Casola leads a research program aimed at identifying the molecular determinants underlying B-cell lymphoma initiation, progression, and therapy resistance.
These studies are conducted using genetically engineered mouse models (many developed within his laboratory) as well as primary mouse and human normal and malignant B cells. Clinical samples are obtained through collaborations with internationally recognized pathologists and hemato-oncologists.
Dr. Casola has made the following major contributions:
• Generated the first transgenic mouse model enabling conditional gene targeting in B cells participating in the germinal center reaction during adaptive immune responses (Casola et al., PNAS, 2006; corresponding author).
• Developed mouse models to investigate the role of Epstein-Barr Virus proteins LMP1 and LMP2A in the pathogenesis of Hodgkin disease and post-transplant EBV-associated lymphoproliferative disorders (Casola et al., Nature Immunology, 2004, corresponding author; Zhang, Casola et al., Cell, 2012, first author).
• Identified microRNA miR-155 as a key regulator of germinal center B-cell responses (Thai et al., Science, 2006; co-author).
• Demonstrated the role of the Polycomb group protein Ezh2 in transcription factor–mediated somatic cell reprogramming (Fragola et al., 2009; corresponding author).
• Elucidated the function of the Polycomb group protein Ezh2 in B-cell adaptive immune responses (Caganova et al., 2013; corresponding author).
• Applied somatic nuclear transfer technology to demonstrate the nuclear plasticity of terminally differentiated antibody-secreting plasma cells (Kumar et al., PNAS, 2015; corresponding author).
• Defined the contribution of VH gene replacement to diversification of the primary mouse immunoglobulin heavy chain repertoire (Kumar et al., PNAS, 2015; corresponding author).
• Revealed the existence of mouse and human Burkitt lymphomas bypassing B-cell receptor (BCR) requirement, providing mechanistic insights into BCR function in MYC-driven lymphomas (Varano et al., Nature, 2017; corresponding author).
• Reconstructed the molecular mechanisms underlying the origin of high-grade B-cell lymphomas with MYC and BCL2 rearrangements (Varano et al., Blood Cancer Discovery, 2025; corresponding author).
• Establishewd the role fo the RAG proteins in the pathogenesis of high-grade B-cell lymphomas with MYC and BCL2 rearrangements (Varano et al., Blood Cancer Discovery, 2025; corresponding author).
• Identified the putative precursor cell of origin for high-grade B-cell lymphomas with MYC and BCL2 rearrangements (Lonardi et al., Leukemia, 2026; corresponding author).

Since his appointment in 2006 as Principal Investigator at IFOM, Dr. Casola has secured continuous competitive funding from major national and international agencies, including the European Research Council (ERC), Horizon 2020, Worldwide Cancer Research (formerly AICR), the Italian Association for Cancer Research (AIRC), the Telethon Foundation, the CARIPLO Foundation, and the Italian Ministry of Health.
Dr. Casola was also awarded a collaborative research grant with Dr. S. Fagarasan (RIKEN Center for Integrative Medical Sciences, Yokohama, Japan), supported by RIKEN.

Over the past 20 years, Dr. Casola’s research unit has established collaborations with leading international groups in B cell biology, lymphoma research, and epigenetics. These include laboratories led by K. Rajewsky (Max Delbrück Center, Berlin), R. Dalla-Favera and L. Pasqualucci (Columbia University, New York), R. Siebert (Ulm University), U. Klein (University of Leeds), M. Schmidt-Supprian (Technical University of Munich), M. Busslinger (Institute of Molecular Pathology, Vienna), D. Hodson (University of Cambridge), T. Kurosaki (Osaka University), S. Fagarasan (RIKEN, Yokohama), D. Kitamura (Tokyo University of Science), M. Hikida (Akita University), and M. Maruyama (National Center for Geriatrics and Gerontology, Nagoya).

Reviewing activity
• 2026–present: Member of the Editorial Board, Communications Biology (Nature Portfolio).
• 2024: Committee Member, evaluation of Interdisciplinary Thematic Institutes, University of Strasbourg, France.
• 2023: Chair, HCERES evaluation committee, Cochin Institute, Paris, France.
• 2022: Chair, HCERES evaluation committee, INSERM/CNRS CIML Unit, Marseille, France.
• 2021: Chair, HCERES evaluation committee, INSERM/CNRS CRIBL Unit, Limoges, France.
• 2021–present: Committee Member, HCERES (High Council for the Evaluation of Research and Higher Education, France).
• 2021–present: Associate Editor, Frontiers in Immunology (B Cell Biology section).
• 2015–2017: Committee Member, Immunology and Infection Panel (CES15), French National Research Agency (ANR).
• 2010–2016: Faculty Member, Faculty of 1000 (Leukocyte Activation section).
• 2006–present: External reviewer for major funding agencies, including the European Research Council (ERC), the Israel Science Foundation (ISF), the Swiss Cancer Research Foundation, and the Czech Science Foundation.

Organization of International Conferences
• 2017: Organizer, 19th International Conference on “Lymphatic Tissues and Germinal Centres in Immune Reactions”, San Servolo, Italy.
• 2009: Organizer, SEMM International Workshop on “Reprogramming Cell Fate: Basic Biology and Medical Perspectives”, Milan, Italy.

Invited Presentations at International Conferences and Workshops
(selected events in the past 6 years)
• 2026: European Hematology Association Annual Meeting, Stockholm, Sweden.
• 2025: CRC 1530 Symposium, Cologne, Germany.
• 2024: American Society of Hematology Annual Meeting, San Diego, CA, USA.
• 2024: Cambridge Lymphoma Biology International Symposium (CLBIS), Cambridge, United Kingdom.
• 2023: 17th International Conference on Malignant Lymphoma, Lugano, Switzerland.
• 2023: European Hematology Association Annual Meeting, Frankfurt, Germany.
• 2022: European Molecular Biology Organization Workshop on “Germinal Centers and Immune Niches”, Weizmann Institute of Science, Rehovot, Israel.
• 2022: SIAPEC Annual Meeting (Italian Society of Pathology), Padua, Italy.
• 2021: European Hematology Association Virtual Annual Meeting
• 2020: American Association for Cancer Research International Meeting on “Advances in Malignant Lymphoma: Maximizing the Basic–Translational Interface for Clinical Application”, Boston, MA, USA.
• 2020: 11th International Symposium, Japanese Society of Hematology, Shimane, Japan.
 
Publications (in reverse chronological order)
1. Soilleux EJ, Anderson A, Roberts E, Lyne L, Wong KK, Spearman H, Casola S, Banham AH, Gascoyne DM. Vitamin D receptor expression in germinal centre type diffuse large B-cell lymphoma cells is associated with vitamin D insensitivity. Endocr Oncol. 2026 Mar 16;6(1):e250057. doi: 10.1530/EO-25-0057. PMID: 41884528;PMCID: PMC13010275.
2. Lonardi S, Cancila V, Morello G, Varano G, Balzarini P, Pellegrini V, Albertini E, Giampaolo S, Pietrini I, Thanasi H, Sindaco P, Piazza F, Manni S, Lorenzini D, Pruneri G, Dei Tos AP, Ponzoni M, Facchetti F, Pizzi M, Lorenzi L, Tripodo C, Casola S. RAG1/2 expression in IGH-switched follicular lymphoma associated with transformation to high-grade B-cell lymphoma. Leukemia. 2026 Mar 6. doi: 10.1038/s41375-026-02896-4. Epub ahead of print. PMID: 41792441.
3. Casola S, Varano G. The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities. Blood Cancer Discov. 2026 Mar 2:OF1-OF14. doi:10.1158/2643-3230.BCD-25-0303. Epub ahead of print. PMID: 41770110.
4. Brambillasca S, Chantal Parr N, Palmeri A, Andronache A, Arima H, Faga' G, Leuzzi B, Perucho L, Robusto M, Pasi M, Mainoldi F, Fancelli D, Varasi M, Varano G, Mercurio C, Casola S. Targetable Vulnerabilities in MYC-Driven B Cell Lymphomas Resistant to BCR Extinction. Hematol Oncol. 2026 Mar;44(2):e70175.doi: 10.1002/hon.70175. PMID: 41668618; PMCID: PMC12892111
5. Cancila V, Bertolazzi G, Chan AS, Medico G, Bastianello G, Morello G, Paysan D, Lai C, Hong L, Shenoy G, Jaynes PW, Schiavoni G, Mattei F, Piconese S, Revuelta MV, Noto F, Businaro L, De Ninno A, Cammarata I, Pagni F, Venkatachalapathy S, Sangaletti S, Di Napoli A, Cicio G, Vacca D, Lonardi S, Lorenzi L, Ferreri AJ, Belmonte B, Liu M, Lakshmanan M, Ong MS, Zhang B, See T, Lam KP, Varano G, Colombo MP, Bicciato S, Inghirami G, Cerchietti L, Ponzoni M, Zappasodi R, Metzger E, Beechem J, Facchetti F, Foiani M, Casola S, Jeyasekharan AD, Tripodo C. Aggressive B cell lymphomas retain ATR-dependent determinants of T cell exclusion from the germinal center dark zone. J Clin Invest. 2025 Jul 17;135(18):e187371. doi: 10.1172/JCI187371.
6. Varano G, Lonardi S, Sindaco P, Pietrini I, Morello G, Balzarini P, Vit F, Neuman H, Bertolazzi G, Brambillasca S, Parr NC, Chiarini M, Bellesi S, Maiolo E, Giampaolo S, Mainoldi F, Selvarasa V, Arima H, Pellegrini V, Pagani C, Bugatti M, Ranise C, Taddei TM, Sonoki T, Thanasi H, Morlacchi E, Segura-Garzon D, Albertini E, Daffini R, Sivacegaram A, Yang H, Li Y, Cancila V, Cicio G, Robusto M, Leuzzi B, Andronache A, Trifiro P, Riboni M, Minardi SP, Bonnal RJP, Gonzalez CL, Visco E, Capaccio P, Torretta S, Pignataro L, Almici C, Varasi M, Larocca LM, Siebert R, Falini B, Ferreri AJM, Tucci A, Lorenzini D, Cabras AD, Pruneri G, Di Napoli A, Ungari M, Pizzi M, Hohaus S, Mercurio C, Song JY, Chan WC, Lorenzi L, Bomben R, Ponzoni M, Mehr R, Tripodo C, Facchetti F, Casola S.B cell receptor silencing reveals the origin of high-grade B cell lymphomas with MYC and BCL2 rearrangements. Blood Cancer Discov. 2025 Jul 1;6(4):364-393. doi: 10.1158/2643-3230.BCD-25-0099
7. Marcos-Kovandzic L, Avagliano M, Ben Khelil M, Srikanthan J, Abdallah R, Petrocelli V, Rengassamy J, Alfaro A, Bied M, Fidelle M, Ferrere G, Daillere R, Arbab A, Amine-Hneineh R, Pages A, Dartigues P, Ly P, Simon S, Durand S, Gottschlich A, Ginhoux F, Bleriot C, Liu P, Zhao L, Creusot L, Rolhion N, Derosa L, Kroemer G, Menger L, Kobold S, Castilla-Llorente C, Sokol H, Casola S, Pasolli E, Zitvogel L, Bigenwald C. Gut microbiota modulation through Akkermansia spp. supplementation increases CAR-T cell potency. Cancer Discov. 2025 Jun 11. doi: 10.1158/2159-8290.CD-24-1230.
8. Pizzi M, Lorenzi L, Scarmozzino F, Albertini E, Santoro L, Mussiolin L, Carraro E, Cutrone C, Casola S, Pillon M, Dei Tos AP. Reactive Bcl2-positive germinal centers in pediatric tonsils: expanding the spectrum of lymphoma mimickers in children and adolescents. Histopathology. 2025 Jul;87(1):145-152. doi: 10.1111/his.15460.
9. Raucci F, Vernieri C, Di Tano M, Ligorio F, Blaževits O, Lazzeri S, Shmahala A, Fragale G, Salvadori G, Varano G, Casola S, Buono R, Visco E, de Braud F, Longo V. Cyclic fasting-mimicking diet (FMD) plus bortezomib and rituximab as an effective treatment for Chronic Lymphocytic Leukemia (CLL). Cancer Res. 2024 Apr 1;84(7):1133-1148. doi: 10.1158/0008-5472.CAN-23-0295.
10. Hariprakash JM, Salviato E, La Mastra F, Sebestyén E, Tagliaferri I, Silva RS, Lucini F, Farina L, Cinquanta M, Rancati I, Riboni M, Minardi SP, Roz L, Gorini F, Lanzuolo C, Casola S, Ferrari F. Leveraging tissue-specific enhancer-target gene regulatory networks identifies enhancer somatic mutations that functionally impact lung cancer. Cancer Res. 2024 Jan 2;84(1):133-153. doi: 10.1158/0008-5472.CAN-23-1129.
11. Lorenzi L, Lonardi S, Bonezzi M, Zini S., Bugatti M., Valzelli A, Melotti F, Facchetti M, Ghini I, Villanacci V, Balzarini P, Pizzi M, Giustini V, Galvagni A. Chiarini M, Dei Tos AP, Vermi W, Casola S, Facchetti F. Immunoglobulin light chain transcript detection by ultrasensitive RNA in situ hybridization for B-cell lymphoma diagnosis Virchows Archiv. 2023 Oct 26. https://doi.org/10.1007/s00428-023-03682-8
12. Huda A , Arakawa H , Mazzucco G , Galli M , Petrocelli V , Casola S , Chen L, Doksani Y. The telomerase reverse transcriptase elongates reversed replication forks at telomeric repeats. Sci Adv. 2023. Mar 22;9(12):eadf2011. doi: 10.1126/sciadv.adf2011.
13. Quotti Tubi L, Mandato E, Canovas Nunes S, Arjomand A, Zaffino F, Manni S, Casellato A, Macaccaro P, Vitulo N, Zumerle S, Filhol O, Boldyreff B, Siebel CW, Viola A, Valle G, Mainoldi F, Casola S, Cancila V, Gulino A, Tripodo C, Pizzi M, Dei Tos AP, Trentin L, Semenzato G, Piazza F. CK2β-regulated signaling controls B cell differentiation and function. Front Immunol. 2023 Jan 11;13:959138. doi: 10.3389/fimmu.2022.959138.
14. Rovito R, Bono V, Augello M, Tincati C, Mainoldi F, Beaudoin-Bussières G, Tauzin A, Bianchi S, Hadla M, Yellenki V, d'Arminio Monforte A, Casola S, Borghi E, Finzi A, Marchetti G. Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients. Sci Rep. 2022 Nov 16;12(1):19658. doi: 10.1038/s41598-022-23923-1..
15. Copperi F, Schleis I, Roumain M, Muccioli GG, Casola S, Klingenspor M, Pfeifer A, Gnad T. EBI2 is a negative modulator of brown adipose tissue energy expenditure in mice and human brown adipocytes. Commun Biol. 2022 Mar 29;5(1):280. doi: 10.1038/s42003-022-03201-6.
16. Facchetti F, Bugatti M, Drera E, Tripodo C, Sartori E, Cancila V, Papaccio M, Castellani R, Casola S, Boniotti MB, Cavadini P, Lavazza A. SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Placenta. EBioMedicine. 2020 Sep;59:102951. doi: 10.1016/j.ebiom.2020.102951.
17. Tripodo C, Zanardi F, Iannelli F, Mazzara S, Vegliante M, Morello G, Di Napoli A, Mangogna A, Facchetti F, Sangaletti S, Chiodoni C, VanShoiack A, Jeyasekharan AD, Casola S, Colombo MP, Ponzoni M, Pileri SA. A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas. iScience. 2020 Sep 16;23(10):101562.doi: 10.1016/j.isci.2020.101562.
18. Cossarizza A, Chang HD, Radbruch A, Acs A, Adam D, Adam-Klages S, Agace WW, Aghaeepour N, Akdis M, Allez M, Almeida LN, Alvisi G, Anderson G, Andrä I, Annunziato F, Anselmo A, Bacher P, Baldari CT, Bari S, Barnaba V, Barros-Martins J, Battistini L, Bauer W, Baumgart S, Baumgarth N, Baumjohann D, Baying B, Bebawy M, Becher B, Beisker W, Benes V, Beyaert R, Blanco A, Boardman DA, Bogdan C, Borger JG, Borsellino G, Boulais PE, Bradford JA, Brenner D, Brinkman RR, Brooks AES, Busch DH, Büscher M, Bushnell TP, Calzetti F, Cameron G, Cammarata I, Cao X, Cardell SL, Casola S, Cassatella MA, Cavani A, Celada A, Chatenoud L, Chattopadhyay PK, Chow S, Christakou E, Čičin-Šain L, Clerici M, Colombo FS, Cook L, Cooke A, Cooper AM, Corbett AJ, Cosma A, Cosmi L, Coulie PG, Cumano A, Cvetkovic L, Dang VD, Dang-Heine C, Davey MS, Davies D, De Biasi S, Del Zotto G, Dela Cruz GV, Delacher M, Della Bella S, Dellabona P, Deniz G, Dessing M, Di Santo JP, Diefenbach A, Dieli F, Dolf A, Dörner T, Dress RJ, Dudziak D, Dustin M, Dutertre CA, Ebner F, Eckle SBG, Edinger M, Eede P, Ehrhardt GRA, Eich M, Engel P, Engelhardt B, Erdei A, Esser C, Everts B, Evrard M, Falk CS, Fehniger TA, Felipo-Benavent M, Ferry H, Feuerer M, Filby A, Filkor K, Fillatreau S, Follo M, Förster I, Foster J, Foulds GA, Frehse B, Frenette PS, Frischbutter S, Fritzsche W, Galbraith DW, Gangaev A, Garbi N, Gaudilliere B, Gazzinelli RT, Geginat J, Gerner W, Gherardin NA, Ghoreschi K, Gibellini L, Ginhoux F, Goda K, Godfrey DI, Goettlinger C, González-Navajas JM, Goodyear CS, Gori A, Grogan JL, Grummitt D, Grützkau A, Haftmann C, Hahn J, Hammad H, Hämmerling G, Hansmann L, Hansson G, Harpur CM, Hartmann S, Hauser A, Hauser AE, Haviland DL, Hedley D, Hernández DC, Herrera G, Herrmann M, Hess C, Höfer T, Hoffmann P, Hogquist K, Holland T, Höllt T, Holmdahl R, Hombrink P, Houston JP, Hoyer BF, Huang B, Huang FP, Huber JE, Huehn J, Hundemer M, Hunter CA, Hwang WYK, Iannone A, Ingelfinger F, Ivison SM, Jäck HM, Jani PK, Jávega B, Jonjic S, Kaiser T, Kalina T, Kamradt T, Kaufmann SHE, Keller B, Ketelaars SLC, Khalilnezhad A, Khan S, Kisielow J, Klenerman P, Knopf J, Koay HF, Kobow K, Kolls JK, Kong WT, Kopf M, Korn T, Kriegsmann K, Kristyanto H, Kroneis T, Krueger A, Kühne J, Kukat C, Kunkel D, Kunze-Schumacher H, Kurosaki T, Kurts C, Kvistborg P, Kwok I, Landry J, Lantz O, Lanuti P, LaRosa F, Lehuen A, LeibundGut-Landmann S, Leipold MD, Leung LYT, Levings MK, Lino AC, Liotta F, Litwin V, Liu Y, Ljunggren HG, Lohoff M, Lombardi G, Lopez L, López-Botet M, Lovett-Racke AE, Lubberts E, Luche H, Ludewig B, Lugli E, Lunemann S, Maecker HT, Maggi L, Maguire O, Mair F, Mair KH, Mantovani A, Manz RA, Marshall AJ, Martínez-Romero A, Martrus G, Marventano I, Maslinski W, Matarese G, Mattioli AV, Maueröder C, Mazzoni A, McCluskey J, McGrath M, McGuire HM, McInnes IB, Mei HE, Melchers F, Melzer S, Mielenz D, Miller SD, Mills KHG, Minderman H, Mjösberg J, Moore J, Moran B, Moretta L, Mosmann TR, Müller S, Multhoff G, Muñoz LE, Münz C, Nakayama T, Nasi M, Neumann K, Ng LG, Niedobitek A, Nourshargh S, Núñez G, O'Connor JE, Ochel A, Oja A, Ordonez D, Orfao A, Orlowski-Oliver E, Ouyang W, Oxenius A, Palankar R, Panse I, Pattanapanyasat K, Paulsen M, Pavlinic D, Penter L, Peterson P, Peth C, Petriz J, Piancone F, Pickl WF, Piconese S, Pinti M, Pockley AG, Podolska MJ, Poon Z, Pracht K, Prinz I, Pucillo CEM, Quataert SA, Quatrini L, Quinn KM, Radbruch H, Radstake TRDJ, Rahmig S, Rahn HP, Rajwa B, Ravichandran G, Raz Y, Rebhahn JA, Recktenwald D, Reimer D, Reis E Sousa C, Remmerswaal EBM, Richter L, Rico LG, Riddell A, Rieger AM, Robinson JP, Romagnani C, Rubartelli A, Ruland J, Saalmüller A, Saeys Y, Saito T, Sakaguchi S, Sala-de-Oyanguren F, Samstag Y, Sanderson S, Sandrock I, Santoni A, Sanz RB, Saresella M, Sautes-Fridman C, Sawitzki B, Schadt L, Scheffold A, Scherer HU, Schiemann M, Schildberg FA, Schimisky E, Schlitzer A, Schlosser J, Schmid S, Schmitt S, Schober K, Schraivogel D, Schuh W, Schüler T, Schulte R, Schulz AR, Schulz SR, Scottá C, Scott-Algara D, Sester DP, Shankey TV, Silva-Santos B, Simon AK, Sitnik KM, Sozzani S, Speiser DE, Spidlen J, Stahlberg A, Stall AM, Stanley N, Stark R, Stehle C, Steinmetz T, Stockinger H, Takahama Y, Takeda K, Tan L, Tárnok A, Tiegs G, Toldi G, Tornack J, Traggiai E, Trebak M, Tree TIM, Trotter J, Trowsdale J, Tsoumakidou M, Ulrich H, Urbanczyk S, van de Veen W, van den Broek M, van der Pol E, Van Gassen S, Van Isterdael G, van Lier RAW, Veldhoen M, Vento-Asturias S, Vieira P, Voehringer D, Volk HD, von Borstel A, von Volkmann K, Waisman A, Walker RV, Wallace PK, Wang SA, Wang XM, Ward MD, Ward-Hartstonge KA, Warnatz K, Warnes G, Warth S, Waskow C, Watson JV, Watzl C, Wegener L, Weisenburger T, Wiedemann A, Wienands J, Wilharm A, Wilkinson RJ, Willimsky G, Wing JB, Winkelmann R, Winkler TH, Wirz OF, Wong A, Wurst P, Yang JHM, Yang J, Yazdanbakhsh M, Yu L, Yue A, Zhang H, Zhao Y, Ziegler SM, Zielinski C, Zimmermann J, Zychlinsky A. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). Eur J Immunol. 2019 Oct;49(10):1457-1973. doi: 10.1002/eji.201970107.
19. Casola S*, Perucho L, Tripodo C, Sindaco P, Ponzoni M, Facchetti F. The B cell receptor in control of tumor B cell fitness: biology and clinical relevance. Immunol Rev. 2019 Mar;288(1):198-213. doi: 10.1111/imr.12738.
20. Vernieri C, Pusceddu S, Fucà G, Indelicato P, Centonze G, Castagnoli, L Ferrari E, Ajazi A, Pupa S, Casola S, Foiani M, Mazzaferro V, Pruneri G, Milione M, de Braud F. Impact of systemic and tumor lipid metabolism on everolimusefficacy in advanced pancreatic neuroendocrine tumors (pNETs). Int J Cancer. 2018. Dec 5. doi: 10.1002/ijc.32042.
21. Catucci I, Osorio A, Arver B, Neidhardt G, Bogliolo M, Zanardi F, Riboni M, Minardi S, Pujol R, Azzollini J, Peissel B, Manoukian S, De Vecchi G, Casola S, Hauke J, Richters L, Rhiem K, Schmutzler RK, Wallander K, Törngren T, Borg Å,Radice P, Surrallés J, Hahnen E, Ehrencrona H, Kvist A, Benitez J, Peterlongo P. Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. Genet Med. 2018 Apr;20(4):452-457. doi: 10.1038/gim.2017.123
22. Petrocelli V, Casola S. Targeting Gene Function in Germinal Center B Cells: A Practical Approach. Methods Mol Biol. 2017;1623:209-231. doi:10.1007/978-1-4939-7095-7_17.
23. Varano G, Raffel S, Sormani M, Zanardi F, Lonardi S, Zasada C, Perucho L,Petrocelli V, Haake A, Lee AK, Bugatti M, Paul U, Van Anken E, Pasqualucci L, Rabadan R, Siebert R, Kempa S, Ponzoni M, Facchetti F, Rajewsky K, Casola S. The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition. Nature. 2017 Jun 8;546(7657):302-306. doi: 10.1038/nature22353.
24. Wanke F, Moos S, Croxford AL, Heinen AP, Gräf S, Kalt B, Tischner D, Zhang J, Christen I, Bruttger J, Yogev N, Tang Y, Zayoud M, Israel N, Karram K, Reißig S, Lacher SM, Reichhold C, Mufazalov IA, Ben-Nun A, Kuhlmann T, Wettschureck N, Sailer AW, Rajewsky K, Casola S*, Waisman A*, Kurschus FC*. EBI2 Is Highly Expressed in Multiple Sclerosis Lesions and Promotes Early CNS Migration of Encephalitogenic CD4 T Cells. Cell Rep. 2017 Jan 31;18(5):1270-1284. doi: 10.1016/j.celrep.2017.01.020.
25. Vernieri C, Casola S, Foiani M, Pietrantonio F, de Braud F, Longo V. Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. Cancer Discov. 2016 Dec;6(12):1315-1333. doi: 10.1158/2159-8290.CD-16-0615.
26. Mihailovich M, Bremang M, Spadotto V, Musiani D, Vitale E, Varano G, Zambelli F, Mancuso FM, Cairns DA, Pavesi G, Casola S, Bonaldi T. miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth. Nat Commun. 2015 Nov 10; 6:8725. doi: 10.1038/ncomms9725.
27. Kumar R, Bach MP, Mainoldi F, Maruya M, Kishigami S, Jumaa H, Wakayama T, Kanagawa O, Fagarasan S, Casola S. Antibody repertoire diversification through VH gene replacement in mice cloned from an IgA plasma cell. Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):E450-7. doi: 10.1073/pnas.1417988112.
28. Alberghini F, Petrocelli V, Rahmat M, Casola S. An epigenetic view of B-cell disorders. Immunol Cell Biol. 2015 Mar; 93(3):253-60. doi: 10.1038/icb.2014.116. Epub 2015 Jan 20.
29. Simonetti G, Bertilaccio MT, Rodriguez TV, Apollonio B, Dagklis A, Rocchi M, Innocenzi A, Casola S, Winkler TH, Nitschke L, Ponzoni M, Caligaris-Cappio F, Ghia P. SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders. Haematologica. 2014 Aug;99(8):1356-64. doi: 10.3324/haematol.2013.100230.
30. Piunti A, Rossi A, Cerutti A, Albert M, Jammula S, Scelfo A, Cedrone L, Fragola G, Olsson L, Koseki H, Testa G, Casola S, Helin K, d'Adda di Fagagna F, Pasini D. Polycomb proteins control proliferation and transformation independently of cell cycle checkpoints by regulating DNA replication. Nat Commun. 2014 Apr 14;5: 3649. doi: 10.1038/ncomms4649.
31. Colombo E, Tentorio P, Musio S, Rajewsky K, Pedotti R, Casola S, Farina C. Skewed B cell differentiation affects lymphoid organogenesis but not T cell-mediated autoimmunity. Clin Exp Immunol. 2014 Apr;176(1):58-65. doi: 10.1111/cei.12250.
32. Caganova M, Carrisi C, Varano G, Mainoldi F, Zanardi F, Germain PL, George L, Alberghini F, Ferrarini L, Talukder AK, Ponzoni M, Testa G, Nojima T, Doglioni C, Kitamura D, Toellner KM, Su IH, Casola S. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J Clin Invest. 2013 Dec;123(12):5009-22. doi: 10.1172/JCI70626. Epub 2013 Nov 8. Erratum in: J Clin Invest. 2014 Apr 1;124(4):1869.
33. Fogli LK, Sundrud MS, Goel S, Bajwa S, Jensen K, Derudder E, Sun A, Coffre M, Uyttenhove C, Van Snick J, Schmidt-Supprian M, Rao A, Grunig G, Durbin J, Casola S, Rajewsky K, Koralov SB. T cell-derived IL-17 mediates epithelial changes in the airway and drives pulmonary neutrophilia. J Immunol. 2013 Sep 15;191(6):3100-11. doi: 10.4049/jimmunol.1301360. Epub 2013 Aug 21. Erratum in: J Immunol. 2013 Nov 15;191(10):5318. Casola, Stefano S [corrected to Casola, Stefano].
34. Fragola G, Germain PL, Laise P, Cuomo A, Blasimme A, Gross F, Signaroldi E, Bucci G, Sommer C, Pruneri G, Mazzarol G, Bonaldi T, Mostoslavsky G, Casola S*, Testa G*. Cell reprogramming requires silencing of a core subset of polycomb targets. PLoS Genet. 2013;9(2):e1003292. doi: 10.1371/journal.pgen.1003292.
35. Pengo N, Scolari M, Oliva L, Milan E, Mainoldi F, Raimondi A, Fagioli C, Merlini A, Mariani E, Pasqualetto E, Orfanelli U, Ponzoni M, Sitia R, Casola S, Cenci S. Plasma cells require autophagy for sustainable immunoglobulin production. Nat Immunol. 2013 Mar;14(3):298-305. doi: 10.1038/ni.2524.
36. Lechouane F, Bonaud A, Delpy L, Casola S, Oruc Z, Chemin G, Cogné M, Sirac C. B-cell receptor signal strength influences terminal differentiation. Eur J Immunol. 2013 Mar;43(3):619-28. doi: 10.1002/eji.201242912.
37. Pozzi B, Amodio S, Lucano C, Sciullo A, Ronzoni S, Castelletti D, Adler T, Treise I, Betsholtz IH, Rathkolb B, Busch DH, Wolf E, Fuchs H, Gailus-Durner V, de Angelis MH, Betsholtz C, Casola S, Di Fiore PP, Offenhäuser N. The endocytic adaptor Eps15 controls marginal zone B cell numbers. PLoS One. 2012;7(11):e50818. doi: 10.1371/journal.pone.0050818.
38. Burgold T, Voituron N, Caganova M, Tripathi PP, Menuet C, Tusi BK, Spreafico F, Bévengut M, Gestreau C, Buontempo S, Simeone A, Kruidenier L, Natoli G, Casola S, Hilaire G, Testa G. The H3K27 demethylase JMJD3 is required for maintenance of the embryonic respiratory neuronal network, neonatal breathing, and survival. Cell Rep. 2012 Nov 29;2(5):1244-58. doi: 10.1016/j.celrep.2012.09.013.
39. Zhang B**, Kracker S**, Yasuda T**, Casola S**, Vanneman M, Hömig-Hölzel C, Wang Z, Derudder E, Li S, Chakraborty T, Cotter SE, Koyama S, Currie T, Freeman GJ, Kutok JL, Rodig SJ, Dranoff G, Rajewsky K. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell. 2012 Feb 17;148(4):739-51. doi: 10.1016/j.cell.2011.12.031.
40. Sakurai N, Maeda M, Lee SU, Ishikawa Y, Li M, Williams JC, Wang L, Su L, Suzuki M, Saito TI, Chiba S, Casola S, Yagita H, Teruya-Feldstein J, Tsuzuki S, Bhatia R, Maeda T. The LRF transcription factor regulates mature B cell development and the germinal center response in mice. J Clin Invest. 2011 Jul;121(7):2583-98. doi: 10.1172/JCI45682.
41. Pasi CE, Dereli-Öz A, Negrini S, Friedli M, Fragola G, Lombardo A, Van Houwe G, Naldini L, Casola S, Testa G, Trono D, Pelicci PG, Halazonetis TD. Genomic instability in induced stem cells. Cell Death Differ. 2011 May;18(5):745-53. doi: 10.1038/cdd.2011.9.
42. Casola S. Mouse models for miRNA expression: the ROSA26 locus. Methods Mol Biol. 2010;667: 145-63. doi: 10.1007/978-1-60761-811-9_10.
43. Grazini U, Zanardi F, Citterio E, Casola S, Goding CR, McBlane F. The RING domain of RAG1 ubiquitylates histone H3: a novel activity in chromatin-mediated regulation of V(D)J joining. Mol Cell. 2010 Jan 29;37(2):282-93. doi: 10.1016/j.molcel.2009.12.035.
44. Omodei D, Acampora D, Russo F, De Filippi R, Severino V, Di Francia R, Frigeri F, Mancuso P, De Chiara A, Pinto A, Casola S, Simeone A. Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma. Am J Pathol. 2009 Dec;175(6):2609-17. doi: 10.2353/ajpath.2009.090542.
45. De Santa F, Narang V, Yap ZH, Tusi BK, Burgold T, Austenaa L, Bucci G, Caganova M, Notarbartolo S, Casola S, Testa G, Sung WK, Wei CL, Natoli G. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J. 2009 Nov 4;28(21):3341-52. doi: 10.1038/emboj.2009.271.
46. Hikida M, Casola S, Takahashi N, Kaji T, Takemori T, Rajewsky K, Kurosaki T. PLC-gamma2 is essential for formation and maintenance of memory B cells. J Exp Med. 2009 Mar 16;206(3):681-9. doi: 10.1084/jem.20082100.
47. Hao Z, Duncan GS, Seagal J, Su YW, Hong C, Haight J, Chen NJ, Elia A, Wakeham A, Li WY, Liepa J, Wood GA, Casola S, Rajewsky K, Mak TW. Fas receptor expression in germinal-center B cells is essential for T and B lymphocyte homeostasis. Immunity. 2008 Oct 17;29(4):615-27. doi: 10.1016/j.immuni.2008.07.016.
48. Hömig-Hölzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, Müller W, Quintanilla-Martinez L, Gewies A, Ruland J, Rajewsky K, Zimber-Strobl U. Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J Exp Med. 2008 Jun 9;205(6):1317-29. doi: 10.1084/jem.20080238.
49. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, Schmidt-Supprian M, Rajewsky N, Yancopoulos G, Rao A, Rajewsky K. Regulation of the germinal center response by microRNA-155. Science. 2007 Apr 27;316(5824):604-8. doi: 10.1126/science.1141229.
50. Casola S. Control of peripheral B-cell development. Curr Opin Immunol. 2007 Apr;19(2):143-9. doi: 10.1016/j.coi.2007.02.010.
51. Casola S, Rajewsky K. B cell recruitment and selection in mouse GALT germinal centers. Curr Top Microbiol Immunol. 2006;308: 155-71. doi: 10.1007/3-540-30657-9_7.
52. Klein U, Casola S, Cattoretti G, Shen Q, Lia M, Mo T, Ludwig T, Rajewsky K, Dalla-Favera R. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol. 2006 Jul;7(7):773-82. doi: 10.1038/ni1357.
53. Casola S, Cattoretti G, Uyttersprot N, Koralov SB, Seagal J, Hao Z, Waisman A, Egert A, Ghitza D, Rajewsky K. Tracking germinal center B cells expressing germ-line immunoglobulin gamma1 transcripts by conditional gene targeting. Proc Natl Acad Sci U S A. 2006 May 9;103(19):7396-401. doi: 10.1073/pnas.0602353103.
54. Novobrantseva TI, Majeau GR, Amatucci A, Kogan S, Brenner I, Casola S, Shlomchik MJ, Koteliansky V, Hochman PS, Ibraghimov A. Attenuated liver fibrosis in the absence of B cells. J Clin Invest. 2005 Nov;115(11):3072-82. doi: 10.1172/JCI24798.
55. Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol. 2004 Aug 15;173(4):2245-52. doi: 10.4049/jimmunol.173.4.2245.
56. Schmidt-Supprian M, Tian J, Ji H, Terhorst C, Bhan AK, Grant EP, Pasparakis M, Casola S, Coyle AJ, Rajewsky K. I kappa B kinase 2 deficiency in T cells leads to defects in priming, B cell help, germinal center reactions, and homeostatic expansion. J Immunol. 2004 Aug 1;173(3):1612-9. doi: 10.4049/jimmunol.173.3.1612.
57. Casola S. Conditional gene mutagenesis in B-lineage cells. Methods Mol Biol. 2004;271: 91-109. doi: 10.1385/1-59259-796-3:091.
58. Casola S, Otipoby KL, Alimzhanov M, Humme S, Uyttersprot N, Kutok JL, Carroll MC, Rajewsky K. B cell receptor signal strength determines B cell fate. Nat Immunol. 2004 Mar;5(3):317-27. doi: 10.1038/ni1036.
59. Vernucci M, Cerrato F, Besnard N, Casola S, Pedone PV, Bruni CB, Riccio A. The H19 endodermal enhancer is required for Igf2 activation and tumor formation in experimental liver carcinogenesis. Oncogene. 2000 Dec 14;19(54):6376-85. doi: 10.1038/sj.onc.1204024.
60. Sperandeo MP, Ungaro P, Vernucci M, Pedone PV, Cerrato F, Perone L, Casola S, Cubellis MV, Bruni CB, Andria G, Sebastio G, Riccio A. Relaxation of insulin-like growth factor 2 imprinting and discordant methylation at KvDMR1 in two first cousins affected by Beckwith-Wiedemann and Klippel-Trenaunay-Weber syndromes. Am J Hum Genet. 2000 Mar;66(3):841-7. doi: 10.1086/302811.
61. Ungaro P, Casola S, Vernucci M, Pedone PV, Bruni CB, Riccio A. Relaxation of insulin-like growth factor-2 imprinting in rat cultured cells. Mol Cell Endocrinol. 1997 Dec 12;135(2):153-63. doi: 10.1016/s0303-7207(97)00201-3.
62. Casola S, Pedone PV, Cavazzana AO, Basso G, Luksch R, d'Amore ES, Carli M, Bruni CB, Riccio A. Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma. Oncogene. 1997 Mar 27;14(12):1503-10. doi: 10.1038/sj.onc.1200956.
63. Zarrilli R, Romano M, Pignata S, Casola S, Bruni CB, Acquaviva AM. Constitutive insulin-like growth factor-II expression interferes with the enterocyte-like differentiation of CaCo-2 cells. J Biol Chem. 1996 Apr 5;271(14):8108-14. PMID: 8626497. doi: 10.1074/jbc.271.14.8108.
64. Casola S, Vernucci M, Ungaro P, Bruni CB, Riccio A. Preferential loss of heterozygosity of chromosome 7 loci in simian virus 40 t/T antigen-induced mouse hepatocellular carcinomas does not involve H-ras mutations. Acta Genet Med Gemellol. 1996;45(1-2):221-5. doi: 10.1017/s0001566000001343.
65. Casola S, Ungaro P, Pedone PV, Lazzaro D, Fattori E, Ciliberto G, Zarrilli R, Bruni CB, Riccio A. Loss of heterozygosity of imprinted genes in SV40 t/T antigen-induced hepatocellular carcinomas. Oncogene. 1995 Aug 17;11(4):711-21. PMID: 7651735.
66. Zarrilli R, Pignata S, Romano M, Gravina A, Casola S, Bruni CB, Acquaviva AM. Expression of insulin-like growth factor (IGF)-II and IGF-I receptor during proliferation and differentiation of CaCo-2 human colon carcinoma cells. Cell Growth Differ. 1994 Oct;5(10):1085-91. PMID: 7848910.
67. Boisclair YR, Brown AL, Casola S, Rechler MM. Three clustered Sp1 sites are required for efficient transcription of the TATA-less promoter of the gene for insulin-like growth factor-binding protein-2 from the rat. J Biol Chem. 1993 Nov 25;268(33):24892-901. PMID: 7693708.
68. Zarrilli R, Casola S, Conti A, Bruni CB, Colantuoni V. Extinction of insulin-like growth factor II gene expression in intratypic hybrids of rat liver cells. Mol Endocrinol. 1993 Jan;7(1):131-41. doi: 10.1210/mend.7.1.8446103.
69. Zarrilli R, Colantuoni V, Faraonio R, Casola S, Rossi E, Bruni CB. Extinction of human insulin-like growth factor II expression in somatic cell hybrids. Adv Exp Med Biol. 1991; 293:77-83. doi: 10.1007/978-1-4684-5949-4_7.